{"disease":{"id":"estrogen-receptor-positive","name":"estrogen receptor positive"},"drugs":{"marketed":[{"drug_id":"palbociclib-in-combination-with-ai","indication_name":"Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women with estrogen receptor-positive (ER+), HER2-negative breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib in combination with AI","generic_name":"palbociclib-in-combination-with-ai","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CDK4/6","drug_class":"CDK inhibitor","quality_score":50,"revenue":"4122","mechanism":""},{"drug_id":"elacestrant","indication_name":"Estrogen receptor positive advanced or metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Orserdu","generic_name":"ELACESTRANT","company_name":"Stemline Therap","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Orserdu works by blocking the estrogen receptor, a protein that helps cancer cells grow."},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic breast cancer in postmenopausal women with one or more estrogen receptors and/or progesterone receptors and a HER2-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04601116","title":"The MASTER Study (MAmmary Cancer STatin ER Positive Study)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":3360,"lead_sponsor_name":"Aarhus University Hospital","has_results":false},{"nct_id":"NCT07391774","title":"Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":1978,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01953588","title":"Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1473,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT03503799","title":"Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1191,"lead_sponsor_name":"North Eastern German Society of Gynaecological Oncology","has_results":false},{"nct_id":"NCT06671912","title":"Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial","phase":"PHASE3","overall_status":"SUSPENDED","enrollment_count":1156,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT06065748","title":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1050,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04546009","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":992,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT00785291","title":"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":799,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03723928","title":"S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":739,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT07340541","title":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT02947685","title":"Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":518,"lead_sponsor_name":"Alliance Foundation Trials, LLC.","has_results":true},{"nct_id":"NCT05306340","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":373,"lead_sponsor_name":"Genentech, Inc.","has_results":false},{"nct_id":"NCT07136493","title":"Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer","phase":"NA","overall_status":"SUSPENDED","enrollment_count":350,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT02216786","title":"A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":333,"lead_sponsor_name":"Queen Mary University of London","has_results":false},{"nct_id":"NCT04086875","title":"A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":332,"lead_sponsor_name":"Thomas Jefferson University","has_results":false},{"nct_id":"NCT04576455","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":303,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT07222215","title":"PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":297,"lead_sponsor_name":"Kristina A. Fanucci","has_results":false},{"nct_id":"NCT00390455","title":"Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":295,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01219699","title":"A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":221,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04571437","title":"Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":204,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT06184750","title":"Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02526498","title":"Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":true},{"nct_id":"NCT02202746","title":"A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":178,"lead_sponsor_name":"Clovis Oncology, Inc.","has_results":true},{"nct_id":"NCT06062498","title":"Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":174,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT03250676","title":"Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":151,"lead_sponsor_name":"Eisai Inc.","has_results":true},{"nct_id":"NCT06474988","title":"Characterization of Biophysical and Mechanical Parameters on Skin of Breast Cancer Patients","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"European Institute of Oncology","has_results":false},{"nct_id":"NCT03644186","title":"To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":147,"lead_sponsor_name":"ETOP IBCSG Partners Foundation","has_results":true},{"nct_id":"NCT07499999","title":"Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":140,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT00676663","title":"Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"Syndax Pharmaceuticals","has_results":true},{"nct_id":"NCT05868226","title":"PRE-I-SPY Phase I/Ib Oncology Platform Program","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":124,"lead_sponsor_name":"QuantumLeap Healthcare Collaborative","has_results":false},{"nct_id":"NCT02945579","title":"Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy","phase":"NA","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06623903","title":"Early Changes in Metabolic Health in Breast Cancer Patients Initiating Endocrine Therapy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":112,"lead_sponsor_name":"Aarhus University Hospital","has_results":false},{"nct_id":"NCT03750396","title":"Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":110,"lead_sponsor_name":"Gangnam Severance Hospital","has_results":false},{"nct_id":"NCT04669587","title":"ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":106,"lead_sponsor_name":"EnhancedBio USA Inc.","has_results":false},{"nct_id":"NCT03584009","title":"A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":103,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04504916","title":"A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":102,"lead_sponsor_name":"VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT02993159","title":"Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Northwestern University","has_results":true},{"nct_id":"NCT04597580","title":"Personalised Disease Monitoring in Metastatic Breast Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":97,"lead_sponsor_name":"The Christie NHS Foundation Trust","has_results":false},{"nct_id":"NCT03106077","title":"Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT03633331","title":"Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":true},{"nct_id":"NCT03886389","title":"Breast Cancer Diet Intervention Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Helse Stavanger HF","has_results":false},{"nct_id":"NCT06028022","title":"Reishi Mushroom Extract for Fatigue and/or Arthralgias/Myalgias in Patients With Breast Cancer on Aromatase Inhibitors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06439693","title":"The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT03395899","title":"Pre-operative Immunotherapy Combination Strategies in Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"Queen Mary University of London","has_results":false},{"nct_id":"NCT03719495","title":"Evaluation of Endocrine Therapy Effects of Host Immunity in Early Stage Breast Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT03285568","title":"Patterns of Prescribing and Monitoring of Palbociclib","phase":"","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Rush University Medical Center","has_results":false},{"nct_id":"NCT02015559","title":"Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT02820961","title":"Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Syndax Pharmaceuticals","has_results":false},{"nct_id":"NCT02997995","title":"Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT00338728","title":"Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}